NYSE · Common Stock · Pharmaceutical Preparations
Israeli pharmaceutical company
26 entities across 16 jurisdictions, 2 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-03 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Anda Inc. | United States | |
| Actavis Group PTC ehf | Iceland | |
| Actavis Pharma Holding 4 ehf | Iceland | |
| Arrow International Limited | Malta | offshore centre |
| Norton Healthcare Limited | United Kingdom | |
| Mepha Pharma AG | Switzerland | |
| Merckle GmbH | Germany | |
| Ratiopharm GmbH | Germany | |
| Salomon, Levin & Elstein Ltd. | Israel | |
| TAPI NL B.V. | Netherlands | |
| Teva Actavis Holding B.V. | Netherlands |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
Bankruptcy-risk screen combining working capital, retained earnings, operating income, market value against liabilities, and asset turnover. Above 2.99 is the safe zone; below 1.81 is distress.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $16.7B | −$4.0B | $638.0M | 46.4% | 1,095,000,000 |
| FY2021 | $15.9B | $417.0M | $236.0M | 47.8% | 1,107,000,000 |
| FY2022 | $14.9B | −$2.4B | $1.0B | 46.7% | 1,110,000,000 |
| FY2023 | $15.8B | −$559.0M | $842.0M | 48.2% | 1,119,000,000 |
| FY2024 | $16.5B | −$1.6B | $749.0M | 48.7% | 1,131,000,000 |
1 institutions tracked — 1 added, 0 reduced.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| ARK Investment Management LLC | Active fund | 68,653 | +374 | $2.3M |
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
TEVA PHARMACEUTICAL INDUSTRIES LTD files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
| Teva Canada Limited | Canada |
| Teva Biotech GmbH | Germany |
| Teva Capital Services Switzerland GmbH | Switzerland |
| Teva Czech Industries s.r.o | Czech Republic |
| Teva Health GmbH | Germany |
| Teva Pharmaceuticals Finance Netherlands B.V. | Netherlands |
| Teva Finance Services II B.V. | Curacao | offshore centre |
| Teva Italia S.r.l | Italy |
| Teva Limited Liability Company | Russia |
| Teva Pharma S.L.U | Spain |
| Teva Pharmaceuticals International GmbH | Switzerland |
| Teva Pharmaceuticals USA, Inc. | United States |
| Teva Operations Poland Sp. Z.o.o. | Poland |
| Teva Santé SAS | France |
| Teva UK Limited | United Kingdom |
| FY2025 |
| $17.3B |
| $1.4B |
| $1.1B |
| 51.8% |
| 1,163,000,000 |